A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors

Ursolic acid liposome (UAL), a new antitumor drug, has potential therapeutic value. However, limited clinical data exists regarding multiple-dose safety, antitumor activity, and the recommended dose (RD) of UAL for subjects with advanced solid tumors. All subjects were intravenously administered UAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Zhengzi, Wang, Xianhuo, Song, Zheng, Zhang, Huilai, Zhou, Shiyong, Zhao, Jing, Wang, Huaqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383362/
https://www.ncbi.nlm.nih.gov/pubmed/25866811
http://dx.doi.org/10.1155/2015/809714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383362/
https://www.ncbi.nlm.nih.gov/pubmed/25866811
http://dx.doi.org/10.1155/2015/809714

Ejemplares similares